The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

A newly developed molecular imaging technique can identify multiple subtypes of triple-negative breast cancer (TNBC), ...

Development of a breakthrough vaccine researchers say could eradicate breast cancer by 2030 wrapped up phase one of its clinical trial this week, with more than 75% of women showing a strong immune ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus ...

New research presented at the 2025 American Society for Clinical Oncology’s (ASCO) annual meeting has shed light on the ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

A groundbreaking vaccine, potentially capable of eradicating breast cancer by 2030, has shown a strong immune response in over 75% of women during its phase one clinical trial.

At the crossroads of innovation and equity, Josette Gbemudu and Merck are helping rewrite the narrative for breast cancer ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...